Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05139056 · ClinicalTrials.gov registry record · Phase 1
Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
A Phase 1 study of Currently Only Enrolling Glioblastoma Patients at First Recurrence, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT05139056: Recruiting Phase 1 study of Currently Only Enrolling Glioblastoma Patients at First Recurrence, sponsored by City of Hope Medical Center.
NCT05139056 is a Phase 1 study of Currently Only Enrolling Glioblastoma Patients at First Recurrence that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05139056, a Phase 1 study of Currently Only Enrolling Glioblastoma Patients at First Recurrence, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase I trial studies the safety of giving multiple intracerebral doses of NSC-CRAd-S-pk7 to treat patients with glioblastoma at first recurrence. NSC-CRAd-S-pk7 consists of neural stem cells that can target glioblastoma cells and carry a virus, which can kill cancer cells. Giving multiple doses of NSC-CRAd-S-pk7 may kill more tumor cells.
Conditions Studied
Interventions
- PROCEDURE Resection
- BIOLOGICAL Neural Stem Cells-expressing CRAd-S-pk7
Study Locations (4)
California
- City of Hope Medical Center - Duarte
- Standford University - Stanford
Illinois
- Northwestern University - Chicago
North Carolina
- Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-05-02 |
| Est. Completion | 2026-08-07 |
| Phase | Phase 1 |
What NCT05139056 shows while recruiting
NCT05139056 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Currently Only Enrolling Glioblastoma Patients at First Recurrence appearing as the primary indexed condition, and to 2 interventions - of which Resection is the first listed.
NCT05139056 reports a single indexed study location in California, Illinois, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05139056 about?
NCT05139056 is a clinical study titled "Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas". This phase I trial studies the safety of giving multiple intracerebral doses of NSC-CRAd-S-pk7 to treat patients with glioblastoma at first recurrence. NSC-CRAd-S-pk7 consists of neural stem cells that can target glioblastoma cells and carry a virus, which can kill cancer cells. Giving multiple dose...
What is the current status of trial NCT05139056?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-05-02. Estimated completion is 2026-08-07.
What conditions does trial NCT05139056 study?
This clinical trial studies the following conditions: Currently Only Enrolling Glioblastoma Patients at First Recurrence.
What interventions are being tested in trial NCT05139056?
The interventions under investigation include: Resection (PROCEDURE), Neural Stem Cells-expressing CRAd-S-pk7 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05139056?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05139056 being conducted?
This trial has 4 study locations across California, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05139056's enrollment target sits among peer trials
36 1211th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI